000161263012-312025Q2falseP3YP6MP1YP1YP1YP1Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesjynt:clinicjynt:corporationjynt:optionxbrli:purejynt:installmentjynt:leasejynt:segmentjynt:franchise00016126302025-01-012025-06-3000016126302025-08-0400016126302025-06-3000016126302024-12-310001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-06-300001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001612630us-gaap:RoyaltyMember2025-04-012025-06-300001612630us-gaap:RoyaltyMember2024-04-012024-06-300001612630us-gaap:RoyaltyMember2025-01-012025-06-300001612630us-gaap:RoyaltyMember2024-01-012024-06-300001612630us-gaap:FranchiseMember2025-04-012025-06-300001612630us-gaap:FranchiseMember2024-04-012024-06-300001612630us-gaap:FranchiseMember2025-01-012025-06-300001612630us-gaap:FranchiseMember2024-01-012024-06-300001612630us-gaap:AdvertisingMember2025-04-012025-06-300001612630us-gaap:AdvertisingMember2024-04-012024-06-300001612630us-gaap:AdvertisingMember2025-01-012025-06-300001612630us-gaap:AdvertisingMember2024-01-012024-06-300001612630us-gaap:TechnologyServiceMember2025-04-012025-06-300001612630us-gaap:TechnologyServiceMember2024-04-012024-06-300001612630us-gaap:TechnologyServiceMember2025-01-012025-06-300001612630us-gaap:TechnologyServiceMember2024-01-012024-06-300001612630us-gaap:ProductAndServiceOtherMember2025-04-012025-06-300001612630us-gaap:ProductAndServiceOtherMember2024-04-012024-06-300001612630us-gaap:ProductAndServiceOtherMember2025-01-012025-06-300001612630us-gaap:ProductAndServiceOtherMember2024-01-012024-06-3000016126302025-04-012025-06-3000016126302024-04-012024-06-3000016126302024-01-012024-06-300001612630us-gaap:CommonStockMember2024-12-310001612630us-gaap:AdditionalPaidInCapitalMember2024-12-310001612630us-gaap:TreasuryStockCommonMember2024-12-310001612630us-gaap:RetainedEarningsMember2024-12-310001612630us-gaap:ParentMember2024-12-310001612630us-gaap:NoncontrollingInterestMember2024-12-310001612630us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001612630us-gaap:ParentMember2025-01-012025-03-3100016126302025-01-012025-03-310001612630us-gaap:CommonStockMember2025-01-012025-03-310001612630us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001612630us-gaap:RetainedEarningsMember2025-01-012025-03-310001612630us-gaap:CommonStockMember2025-03-310001612630us-gaap:AdditionalPaidInCapitalMember2025-03-310001612630us-gaap:TreasuryStockCommonMember2025-03-310001612630us-gaap:RetainedEarningsMember2025-03-310001612630us-gaap:ParentMember2025-03-310001612630us-gaap:NoncontrollingInterestMember2025-03-3100016126302025-03-310001612630us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001612630us-gaap:ParentMember2025-04-012025-06-300001612630us-gaap:CommonStockMember2025-04-012025-06-300001612630us-gaap:RetainedEarningsMember2025-04-012025-06-300001612630us-gaap:CommonStockMember2025-06-300001612630us-gaap:AdditionalPaidInCapitalMember2025-06-300001612630us-gaap:TreasuryStockCommonMember2025-06-300001612630us-gaap:RetainedEarningsMember2025-06-300001612630us-gaap:ParentMember2025-06-300001612630us-gaap:NoncontrollingInterestMember2025-06-300001612630us-gaap:CommonStockMember2023-12-310001612630us-gaap:AdditionalPaidInCapitalMember2023-12-310001612630us-gaap:TreasuryStockCommonMember2023-12-310001612630us-gaap:RetainedEarningsMember2023-12-310001612630us-gaap:ParentMember2023-12-310001612630us-gaap:NoncontrollingInterestMember2023-12-3100016126302023-12-310001612630us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001612630us-gaap:ParentMember2024-01-012024-03-3100016126302024-01-012024-03-310001612630us-gaap:CommonStockMember2024-01-012024-03-310001612630us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001612630us-gaap:RetainedEarningsMember2024-01-012024-03-310001612630us-gaap:CommonStockMember2024-03-310001612630us-gaap:AdditionalPaidInCapitalMember2024-03-310001612630us-gaap:TreasuryStockCommonMember2024-03-310001612630us-gaap:RetainedEarningsMember2024-03-310001612630us-gaap:ParentMember2024-03-310001612630us-gaap:NoncontrollingInterestMember2024-03-3100016126302024-03-310001612630us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001612630us-gaap:ParentMember2024-04-012024-06-300001612630us-gaap:CommonStockMember2024-04-012024-06-300001612630us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001612630us-gaap:RetainedEarningsMember2024-04-012024-06-300001612630us-gaap:CommonStockMember2024-06-300001612630us-gaap:AdditionalPaidInCapitalMember2024-06-300001612630us-gaap:TreasuryStockCommonMember2024-06-300001612630us-gaap:RetainedEarningsMember2024-06-300001612630us-gaap:ParentMember2024-06-300001612630us-gaap:NoncontrollingInterestMember2024-06-3000016126302024-06-300001612630us-gaap:FranchisedUnitsMember2025-03-310001612630us-gaap:FranchisedUnitsMember2024-03-310001612630us-gaap:FranchisedUnitsMember2024-12-310001612630us-gaap:FranchisedUnitsMember2023-12-310001612630us-gaap:FranchisedUnitsMember2025-04-012025-06-300001612630us-gaap:FranchisedUnitsMember2024-04-012024-06-300001612630us-gaap:FranchisedUnitsMember2025-01-012025-06-300001612630us-gaap:FranchisedUnitsMember2024-01-012024-06-300001612630us-gaap:FranchisedUnitsMember2025-06-300001612630us-gaap:FranchisedUnitsMember2024-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2025-03-310001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2024-03-310001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2024-12-310001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2023-12-310001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2024-06-300001612630jynt:KansasCityMemberus-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:EntityOperatedUnitsMember2025-01-012025-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-04-012025-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-04-012024-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-01-012025-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-06-300001612630jynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-3100016126302024-01-012024-12-310001612630srt:MinimumMember2025-06-300001612630srt:MaximumMember2025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:FiniteLivedIntangibleAssetsMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:FiniteLivedIntangibleAssetsMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:AssetsHeldForSaleMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:AssetsHeldForSaleMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:AssetsHeldForSaleMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:AssetsHeldForSaleMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2024-12-310001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:FiniteLivedIntangibleAssetsMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630jynt:DiscontinuedOperationsHeldForUseMemberus-gaap:FiniteLivedIntangibleAssetsMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberus-gaap:PropertyPlantAndEquipmentMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberjynt:OperatingLeaseRightOfUseAssetMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:SegmentDiscontinuedOperationsMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:SegmentDiscontinuedOperationsMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:SegmentDiscontinuedOperationsMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:SegmentDiscontinuedOperationsMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:TransferredAtPointInTimeMember2025-04-012025-06-300001612630us-gaap:TransferredAtPointInTimeMember2024-04-012024-06-300001612630us-gaap:TransferredAtPointInTimeMember2025-01-012025-06-300001612630us-gaap:TransferredAtPointInTimeMember2024-01-012024-06-300001612630us-gaap:TransferredOverTimeMember2025-04-012025-06-300001612630us-gaap:TransferredOverTimeMember2024-04-012024-06-300001612630us-gaap:TransferredOverTimeMember2025-01-012025-06-300001612630us-gaap:TransferredOverTimeMember2024-01-012024-06-3000016126302025-07-012025-06-3000016126302026-01-012025-06-3000016126302027-01-012025-06-3000016126302028-01-012025-06-3000016126302029-01-012025-06-3000016126302030-01-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630jynt:CorporateClinicsMember2025-04-012025-06-300001612630jynt:CorporateClinicsMember2024-04-012024-06-300001612630jynt:CorporateClinicsMember2025-01-012025-06-300001612630jynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMember2024-12-310001612630jynt:CorporateClinicsMember2025-06-300001612630jynt:CorporateClinicsMember2024-12-310001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberjynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2025-01-012025-06-300001612630us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberjynt:CorporateClinicsMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2025-04-012025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2024-04-012024-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMember2024-01-012024-06-300001612630us-gaap:OfficeEquipmentMember2025-06-300001612630us-gaap:OfficeEquipmentMember2024-12-310001612630us-gaap:LeaseholdImprovementsMember2025-06-300001612630us-gaap:LeaseholdImprovementsMember2024-12-310001612630us-gaap:SoftwareDevelopmentMember2025-06-300001612630us-gaap:SoftwareDevelopmentMember2024-12-310001612630jynt:PropertyPlantAndEquipmentExcludingConstructionInProgressMember2025-06-300001612630jynt:PropertyPlantAndEquipmentExcludingConstructionInProgressMember2024-12-310001612630us-gaap:ValuationTechniqueDiscountedCashFlowMember2025-06-300001612630us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:FairValueInputsLevel2Member2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:FairValueInputsLevel3Member2025-06-300001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:FairValueInputsLevel2Member2024-12-310001612630us-gaap:DiscontinuedOperationsHeldforsaleMemberjynt:CorporateClinicsMemberus-gaap:FairValueInputsLevel3Member2024-12-310001612630us-gaap:SecuredDebtMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-02-280001612630jynt:DevelopmentLineOfCreditMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-02-280001612630us-gaap:LetterOfCreditMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:LetterOfCreditMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:LetterOfCreditMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:SecuredDebtMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:SecuredDebtMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2022-02-280001612630jynt:DevelopmentLineOfCreditMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMemberjynt:A2022CreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMemberjynt:A2022CreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:FederalReserveBankOfNewYorkRateMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:ReclassificationOtherMember2021-12-310001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2024-01-170001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2025-06-300001612630us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001612630us-gaap:EmployeeStockOptionMember2025-06-300001612630us-gaap:EmployeeStockOptionMember2024-12-310001612630us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001612630us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001612630us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001612630us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001612630us-gaap:RestrictedStockMember2025-06-300001612630jynt:CertainExecutiveEmployeesMemberus-gaap:RestrictedStockMember2024-03-052024-03-050001612630jynt:CertainExecutiveEmployeesMemberus-gaap:RestrictedStockMember2024-03-050001612630srt:DirectorMemberus-gaap:RestrictedStockMember2025-01-012025-06-300001612630us-gaap:RestrictedStockMember2024-12-310001612630us-gaap:RestrictedStockMember2025-01-012025-06-300001612630us-gaap:RestrictedStockMember2025-04-012025-06-300001612630us-gaap:RestrictedStockMember2024-04-012024-06-300001612630us-gaap:RestrictedStockMember2024-01-012024-06-300001612630jynt:EmploymentMattersMember2024-04-012024-06-300001612630jynt:MedicalInjuryClaimMember2025-02-252025-02-250001612630jynt:MedicalInjuryClaimMember2024-12-310001612630jynt:FranchiseOperationsMember2025-04-012025-06-300001612630jynt:FranchiseOperationsMember2024-04-012024-06-300001612630jynt:FranchiseOperationsMember2025-01-012025-06-300001612630jynt:FranchiseOperationsMember2024-01-012024-06-300001612630us-gaap:FranchiseMemberjynt:FranchiseOperationsMember2025-04-012025-06-300001612630us-gaap:FranchiseMemberjynt:FranchiseOperationsMember2024-04-012024-06-300001612630us-gaap:FranchiseMemberjynt:FranchiseOperationsMember2025-01-012025-06-300001612630us-gaap:FranchiseMemberjynt:FranchiseOperationsMember2024-01-012024-06-300001612630us-gaap:TechnologyServiceMemberjynt:FranchiseOperationsMember2025-04-012025-06-300001612630us-gaap:TechnologyServiceMemberjynt:FranchiseOperationsMember2024-04-012024-06-300001612630us-gaap:TechnologyServiceMemberjynt:FranchiseOperationsMember2025-01-012025-06-300001612630us-gaap:TechnologyServiceMemberjynt:FranchiseOperationsMember2024-01-012024-06-300001612630jynt:BanderaPartnersLLCMembersrt:DirectorMember2025-06-300001612630us-gaap:RelatedPartyMemberus-gaap:FranchisedUnitsMemberjynt:FranchiseLicensesMember2025-06-300001612630jynt:FranchiseLicensesSoldMemberus-gaap:RelatedPartyMember2020-12-012020-12-310001612630jynt:FranchiseLicensesTransferredMemberus-gaap:RelatedPartyMember2022-06-012022-06-300001612630jynt:FranchiseLicensesThreeTransferFeeMemberus-gaap:RelatedPartyMember2022-06-012022-06-300001612630jynt:FranchiseLicensesTwoTransferFeeMemberus-gaap:RelatedPartyMember2022-06-012022-06-300001612630jynt:FranchiseLicensesOneTransferFeeMemberus-gaap:RelatedPartyMember2022-06-012022-06-300001612630jynt:FranchiseLicensesProratedFranchiseLicenseFeesMemberus-gaap:RelatedPartyMember2022-06-012022-06-300001612630jynt:UnaffiliatedFranchiseeMemberjynt:MrJeffersonGrammMember2020-10-310001612630jynt:UnaffiliatedFranchiseeMember2020-10-012020-10-310001612630jynt:UnaffiliatedFranchiseeMemberjynt:MrJeffersonGrammMember2025-06-30

(Mark One)

☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025 

OR

☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to _________________

Commission file number: 001-36724

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No ☑

As of August 4, 2025, the registrant had 15,343,377 shares of Common Stock ($0.001 par value) outstanding.

•the expected adoption and impact of recent accounting pronouncements;

•our plan to continue our rapid and franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry;

•our belief that our monthly performance reports from our system and our clinics include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage and membership attrition;

•our plan to refranchise or sell the full portfolio of our company-owned or managed clinics, which refined strategy will leverage our greatest strength - our capacity to build a franchise - to drive long-term growth for both our franchisees and The Joint as a public company;

•our plan to continue to leverage the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country;

•our belief that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness;

•our belief that these trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model resulting in a combination that benefits the consumer and the service provider alike, and our belief that these forces create an important opportunity to accelerate the growth of our network;

•our belief that recent events that may impact our business include unfavorable global economic or political conditions, such as uncertainties that come with changes to the presidential administration, labor shortages, and inflation and other cost increases;

•our anticipation that 2025 will continue to be a volatile macroeconomic environment;

•our belief that we have created a robust framework for the refranchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency, and that we have received significant interest to date from our existing franchisees;

•our goal to generate significant processes that will provide us with value creating capital allocation opportunities, which opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of regional development territories, certain merger or acquisition opportunities and/or a stock repurchase program;

•our belief that our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns;

•our belief that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months;

•our belief that we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business;

•our expectation that for the remainder of 2025, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change

•the nationwide labor shortage has negatively impacted our ability to recruit chiropractors and other qualified personnel, which may limit our growth strategy, and the measures we have taken in response to the labor shortage have reduced our net revenues;

•inflation leading to increased labor costs and interest rates, as well as changes to import tariffs, may lead to reduced discretionary spending, all of which may negatively impact our business;

•we may not be able to successfully implement our growth strategy if our franchisees are unable to locate and secure appropriate sites for clinic locations, obtain favorable lease terms, and attract patients to our clinics;

•we have restated our prior consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on our stock price;

•we have limited experience operating company-owned or managed clinics in those geographic areas where we currently have few or no clinics, and we may not be able to duplicate the success of some of our franchisees;

•our expectation that our remediation actions over the design of our affected controls will successfully remediate the material weakness;

•short-selling strategies and negative opinions posted on the internet may drive down the market price of our common stock and could result in class action lawsuits;

•we have identified a material weakness in our internal controls over financial reporting and we may fail to remediate future material weaknesses in our internal controls over financial reporting or may otherwise be unable to maintain an effective system of internal control over financial reporting, which might negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence;

•we may fail to successfully design and maintain our proprietary and third-party management information systems or implement new systems;

•we may fail to properly maintain the integrity of our data or to strategically implement, upgrade or consolidate existing information systems;

•we may not be able to continue to sell franchises to qualified franchisees, and our franchisees may not succeed in developing profitable territories and clinics;

•new clinics may not reach the point of profitability, and we may not be able to maintain or improve revenues and franchise fees from existing franchised clinics;

•the chiropractic industry is highly competitive, with many well-established independent competitors, which could prevent us from increasing our market share or result in reduction in our market share;

•state administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize our business model;

•expected new federal regulations and state laws and regulations regarding joint employer responsibility could negatively impact the franchise business model, increasing our potential liability for employment law violations by our franchisees and the likelihood that we may be required to participate in collective bargaining with our franchisees’ employees;

•an increased regulatory focus on the establishment of fair franchise practices could increase our risk of liability in disputes with franchisees and the risk of enforcement actions and penalties;

•negative publicity or damage to our reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models, could adversely impact our operations and financial position;

•our IT security systems and those of our third-party service providers (as recently experienced by one of our marketing vendors) may be breached, and we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract and retain patients; and

•legislation and regulations, as well as new medical procedures and techniques, could reduce or eliminate our competitive advantages.

The following table represents supplemental cash flow disclosures and non-cash investing and financing activities:

These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”), which includes its variable interest entities (“VIEs”), and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the “Company”). The accompanying unaudited condensed consolidated financial statements reflect all adjustments which are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Such unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary and Affiliates consolidated financial statements and the notes thereto as set forth in The Joint’s amended and restated Annual Report on Form 10-K/A as of and for the year ended December 31, 2024, filed with the SEC on August 11, 2025, which included all disclosures required by GAAP. The results of operations for the periods ended June 30, 2025 and 2024, are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the three and six-month periods ended June 30, 2025 and 2024, is unaudited.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management’s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates. For a discussion of significant estimates and judgments, refer to the Use of Estimates section below included in this Note.

The results of operations of the corporate clinic segment are reported in Income from discontinued operations before income tax expense in its condensed consolidated income statement for all periods presented and the related assets and liabilities associated with discontinued operations are classified as discontinued operation assets and liabilities, current and noncurrent, in the condensed consolidated balance sheets at June 30, 2025 and December 31, 2024. The condensed consolidated statement of cash flows includes cash flows related to the discontinued operations and accordingly, cash flow amounts for discontinued operations are disclosed in Note 3, Divestitures. All results and information in the condensed consolidated financial statements are presented as continuing operations and exclude the corporate clinic segment unless otherwise noted specifically as discontinued operations. For additional information, refer to Note 3, Divestitures.

The accompanying condensed consolidated financial statements include the accounts of The Joint and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC, which was dormant for all periods presented. The Company consolidates VIEs in which the Company is the primary beneficiary in accordance with Accounting Standards Codification ("ASC") 810, Consolidations. Non-controlling interests represent third-party equity ownership interests in VIEs. All significant inter-affiliate accounts and transactions between The Joint and its VIEs have been eliminated in consolidation.

Net income was the same as comprehensive income for the three and six months ended June 30, 2025 and 2024, respectively.

The Joint Corp., a Delaware corporation, was formed on March 10, 2010, for the principal purpose of franchising and developing chiropractic clinics, selling regional developer rights, supporting the operations of franchised chiropractic clinics, and operating and managing corporate chiropractic clinics at locations throughout the United States. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.

The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed clinics for the three and six months ended June 30, 2025 and 2024:

Certain states prohibit the “corporate practice of chiropractic,” which restricts business corporations from practicing chiropractic care by exercising control over clinical decisions by chiropractic doctors. In states that prohibit the corporate practice of chiropractic, the Company typically enters into long-term management agreements with professional corporations (“PCs”) that are owned by licensed chiropractic doctors, which, in turn, employ or contract with doctors who provide professional chiropractic care in its clinics. Under these management agreements with PCs, the Company provides, on an exclusive basis, all non-clinical services of the chiropractic practice. The Company has entered into such management agreements with four PCs. In connection with the sale of five company owned or managed clinics in the Kansas City region, the Company terminated its management agreement with one PC as of June 30, 2025. For additional information on clinic sales, refer to Note 3, Divestitures. If an entity is deemed to be the primary beneficiary of a VIE, the entity is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. In accordance with relevant accounting guidance, these PCs were determined to be VIEs, as fees paid by the PCs to the Company as its management service provider are considered variable interests because the fees do not meet all the following criteria: (1) the fees are compensation for services provided and are commensurate with the level of effort required to provide those services; (2) the decision maker or service provider does not hold other interests in the VIE that individually, or in the aggregate, would absorb more than an insignificant amount of the VIE’s expected losses or receive more than an insignificant amount of the VIE’s expected residual returns; and (3) the service arrangement includes only terms, conditions, or amounts that are customarily present in arrangements for similar services negotiated at arm’s length. Additionally, the Company has determined that it has the ability to direct the activities that most significantly impact the performance of these PCs and has an obligation to absorb losses or receive benefits which could potentially be significant to the PCs. Accordingly, the PCs are VIEs for which the Company is the primary beneficiary and are consolidated by the Company.

The revenues of VIEs represent the revenues of company-managed clinics in states that prohibit the corporate practice of chiropractic. The Company’s involvement with VIEs affects its financial performance and cash flows primarily through amounts recorded as revenues from company-owned or managed clinics and general and administrative expenses, which are principally comprised of payroll and related expenses, merchant card fees and insurance expense, all of which are reported in Income from discontinued operations before income tax expense in its condensed consolidated income statement. The management fees/income provided by the management agreements are considered intercompany transactions and therefore eliminated upon consolidation of VIEs.

VIE net income (including the management fee) for the three and six months ended June 30, 2025 and 2024, respectively, is included in Income from discontinued operations before income tax expense and Income tax expense from discontinued operations in the condensed consolidated income statements as follows:

The carrying amount of the VIEs’ assets and liabilities is included in discontinued operations as of June 30, 2025 and December 31, 2024, in the condensed consolidated balance sheets as follows:

The Company considers all highly liquid instruments purchased with a maturity of three months or less at the date of purchase to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of its cash in short-term bank deposits. The Company had no cash equivalents as of June 30, 2025 and December 31, 2024.

Restricted cash relates to cash that franchisees and company-owned or managed clinics contribute to the Company’s National Marketing Fund and cash that franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Company’s Franchise Disclosure Document with a focus on regional and national marketing and advertising. While such cash balance is not legally segregated and restricted as to withdrawal or usage, the Company’s accounting policy is to classify these funds as restricted cash.

Accounts receivable primarily represents amounts due from franchisees for royalty fees. The Company records an allowance for credit losses as a reduction to its accounts receivables for amounts that the Company does not expect to recover. An allowance for credit losses is determined through assessments of collectability based on historical trends, the financial condition of the Company’s franchisees, including any known or anticipated bankruptcies and an evaluation of current economic conditions, as well as the Company’s expectations of conditions in the future. Actual losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. The Company had an allowance for expected credit losses of $0.2 million and $0.2 million as of June 30, 2025 and December 31, 2024, respectively.

The following table provides a reconciliation of the activity related to the Company’s accounts receivable allowance for credit losses:

Property and equipment are stated at cost and relate mostly to the corporate headquarters leasehold improvements, its furniture and fixtures and other office and computer equipment. Depreciation is computed using the straight-line method over estimated useful lives, which is generally three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Maintenance and repairs are charged to expense as incurred, while major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income. The Company recorded losses on disposition or impairment of $4,440 and $6,413 in its condensed consolidated income statement related to continuing operations property or equipment disposed of other than by sale or retirement related to continuing operations for the three and six months ended June 30, 2025, respectively. Losses on disposition or impairment for the three and six months ended June 30, 2024 were not material.

The Company leases property and equipment under operating and finance leases. The Company leases its corporate office space and the space for each of the company-owned or managed clinics in the portfolio. The Company recognizes a right-of-use ("ROU") asset and lease liability for all leases. The lease for its corporate office space is recognized as a ROU and lease liability in its condensed consolidated balance sheet as continuing operations while all other leases for each of the company-owned or managed clinics are reported in discontinued operations. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company’s sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the ROU asset and lease liability. When available, the Company uses the rate implicit in the lease to discount lease payments; however, the rate implicit in the lease is not readily determinable for substantially all of its leases. In such cases, the Company estimates its incremental borrowing rate as the interest rate it would pay to borrow an amount equal to the lease payments over a similar term, with similar collateral as in the lease and in a similar economic environment. The Company estimates these rates using available evidence such as rates imposed by third-party lenders to the Company in recent financings or observable risk-free interest rate and credit spreads for commercial debt of a similar duration, with credit spreads correlating to the Company’s estimated creditworthiness.

For operating leases that include rent holidays and rent escalation clauses, the Company recognizes lease expense on a straight-line basis over the lease term from the date it takes possession of the leased property. Pre-opening costs are recorded as incurred in general and administrative expenses. Variable lease payments, such as percentage rentals based on location sales, periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased corporate office space are expensed as incurred in general and administrative expenses on the condensed consolidated income statements. Any variable costs associated with the leased property for company-owned or managed clinics are expensed as incurred and are included in Income from discontinued operations before income tax expense in its consolidated income statement.

During the three and six months ended June 30, 2025, certain leases related to discontinued operations were terminated early with the landlord as a result of corporate clinic closures. The net losses to terminate the leases were recorded in Income from discontinued operations before income tax in its condensed consolidated income statement of $0.2 million and $0.4 million for the three and six months ended June 30, 2025, respectively.

No leases were terminated during the three and six months ended June 30, 2024.

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets are recoverable. The Company records an impairment loss when the carrying amount of the asset is not recoverable and exceeds its fair value. No impairment losses on long-lived assets were recognized from continuing operations during the three and six months ended June 30, 2025 and 2024.

During the three and six months ended June 30, 2024, property and equipment, net related to asset groups determined to not be recoverable were written down from their carrying values to their respective fair values resulting in the following non-cash impairment losses:

Long-lived assets that meet the criteria for the held for sale designation are reported at the lower of their carrying value or fair value less estimated cost to sell. As a result of its evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the agreed upon sales prices or the clinics estimated fair values, the Company recorded an estimated net loss on disposal, which is included in Income from discontinued operations before income tax expense in its condensed consolidated income statement as follows:

A valuation allowance of $5.7 million and $5.1 million as of June 30, 2025 and December 31, 2024, respectively, are included in Discontinued operations current assets on its condensed consolidated balance sheet.

The following table shows a reconciliation of the Company’s impairment and disposal losses recorded in Income from discontinued operations before income tax expense for the three and six months ended June 30, 2025 and 2024:

The Company generates revenue primarily through company-owned or managed clinics and through royalties, franchise fees, advertising fund contributions, IT-related income and computer software fees from its franchisees.

Revenues from Company-Owned or Managed Clinics. The Company earns revenues from clinics that it owns and operates or manages throughout the United States. Revenues from clinics that the Company owns and operates are recognized when services are performed and are related to discontinued operations. The Company offers a variety of membership and wellness packages, which feature discounted pricing as compared with its single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed. Any unused visits associated with monthly memberships are recognized on a month-to-month basis. The Company recognizes a contract liability (or a deferred revenue liability) related to the prepaid treatment plans for which the Company has an ongoing performance obligation. The Company derecognizes this contract liability and recognizes revenue, as the patient consumes his or her visits related to the package and the Company transfers its services. If the Company determines that it is not subject to unclaimed property laws for the portion of wellness package that it does not expect to be redeemed (referred to as “breakage”), then it recognizes breakage revenue in proportion to the pattern of exercised rights by the patient.

Royalties and Advertising Fund Revenue. The Company collects royalties as stipulated in the franchise agreement, equal to 7% of gross sales and a marketing and advertising fee currently equal to 2% of gross sales. Royalties, including franchisee contributions to advertising funds, are calculated as a percentage of clinic sales over the term of the franchise agreement. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which generally requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price). As the franchise agreement royalties, inclusive of advertising fund contributions, represent sales-based royalties that are related entirely to the Company’s performance obligation under the franchise agreement, such sales-based royalties are recognized as franchisee clinic level sales occur.

Royalties are collected semi-monthly, two working days after each sales period has ended.

Franchise Fees. The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of 10 years. Initial franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement. The Company’s services under the franchise agreement include training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation. Renewal franchise fees, as well as transfer fees, are also recognized as revenue on a straight-line basis over the term of the respective franchise agreement.

Software Fees. The Company collects a monthly fee from its franchisees for use of its proprietary chiropractic software, computer support and internet services support. These fees are recognized ratably on a straight-line basis over the term of the respective franchise agreement.

Capitalized Sales Commissions. Sales commissions earned by the regional developers and the Company’s sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.

The Company has a regional developer program where regional developers are granted an exclusive geographical territory and commit to a minimum development obligation within that defined territory. Upon receiving exclusive rights to develop a territory, a regional developer will pay an upfront fee to the Company. Upfront regional developer fees represent consideration received from a vendor to act as the Company’s agent within an exclusive territory. The upfront regional developer fee is accounted for as a reduction of cost of revenues, in franchise and regional development cost of revenues, to offset the respective future commissions paid to the regional developer. The fees are ratably recognized over the term of the related regional developer agreement.

Regional developers receive fees that are funded by the initial franchise fees collected from franchisees upon the sale of franchises within their exclusive geographical territory and a royalty of 3% of sales generated by franchised clinics in their exclusive geographical territory. Initial fees related to the sale of franchises within their exclusive geographical territory are initially deferred as deferred franchise costs and are recognized as an expense in franchise cost of revenues when the respective revenue is recognized, which is generally over the term of the related franchise agreement. Royalties of 3% of sales generated by franchised clinics in their regions are also recognized as franchise cost of revenues as franchisee clinic level sales occur. This 3% fee is funded by the 7% royalties we collect from the franchisees in their regions. Certain regional developer agreements result in the regional developer acquiring the rights to existing royalty streams from clinics already open in the respective territory. In those instances, fees collected from the sale of the royalty stream is recognized as a decrease to franchise and regional developer cost of revenues over the remaining life of the respective franchise agreements. The Company did not enter into any new regional developer agreements during the three and six months ended June 30, 2025 and 2024.

From time to time, subject to the Company’s strategy, regional developer rights are reacquired by the Company, resulting in a termination of the contract. The termination costs to reacquire the regional developer rights are recognized at fair value, less any unrecognized upfront regional developer fee liability balance, as a general and administrative expense in the period in which the contract is terminated in accordance with the contract terms and are recorded within general and administrative expenses in the condensed consolidated income statements. When regional developer rights are reacquired in conjunction with the sale of company owned or managed clinics, the upfront regional developer fee liability balance at the time of the sale are treated as relieved and are included with the total consideration received when the Company calculates the gain or loss on the sale. The Company reacquired certain regional developer rights during the three months ended June 30, 2025 in conjunction with the sale of company owned or managed clinics. Refer to Note 3, Divestitures for additional information.

Advertising costs are advertising and marketing expenses incurred by the Company, primarily through advertising funds. The Company expenses production costs of commercial advertising upon first airing and expenses the costs of communicating the advertising in the period in which the advertising occurs. Advertising expenses, excluding national marketing fund costs, were $0.4 million and $0.5 million for the three and six months ended June 30, 2025, respectively.

Advertising expenses, excluding national marketing fund costs, were $0.3 million and $0.4 million for the three and six months ended June 30, 2024, respectively.

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date pre-tax income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected pre-tax income for the year and permanent differences. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or the tax environment changes. Refer to Note 12, Subsequent Events for additional information on U.S. legislation signed into law after the three months ended June 30, 2025.

Basic earnings (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per common share is computed by giving effect to all potentially dilutive common shares including restricted stock and stock options.

The following common stock equivalents were excluded from the computation of diluted earnings (loss) per share for the periods presented because including them would have been antidilutive:

The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using the closing price on the date of the grant and the grant-date fair value of stock options using the Black-Scholes-Merton model.

In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.

ASC Topic 450 governs the disclosure of loss contingencies and accrual of loss contingencies in respect of litigation and other claims. The Company records an accrual for a potential loss when it is probable that a loss will occur and the amount of the loss can be reasonably estimated. When the reasonable estimate of the potential loss is within a range of amounts, the minimum of the range of potential loss is accrued, unless a higher amount within the range is a better estimate than any other amount within the range. Moreover, even if an accrual is not required, the Company provides additional disclosure related to litigation and other claims when it is reasonably possible (i.e., more than remote) that the outcomes of such litigation and other claims include potential material adverse impacts on the Company. Legal costs to be incurred in connection with a loss contingency are expensed as such costs are incurred.

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include loss contingencies, share-based compensations, useful lives and realizability of long-lived assets, deferred revenue and revenue recognition related to breakage, deferred franchise costs, calculation of ROU assets and liabilities related to leases, realizability of deferred tax assets, impairment of goodwill, intangible assets and other long-lived assets, and purchase price allocations and related valuations. Deferred revenue related to breakage, goodwill and intangible assets are related to discontinued operations. Refer to Note 3, Divestitures for more information on discontinued operations.

In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires public entities with a single reportable segment to provide all the disclosures required by this standard and all existing segment disclosures in Topic 280 on an interim and annual basis, including new requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within the reported measure(s) of a segment's profit or loss, the amount and composition of any other segment items, the title and position of the CODM and how the CODM uses the reported measure(s) of a segment’s profit or loss to assess performance and decide how to allocate resources. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, applied retrospectively with early adoption permitted. The Company adopted ASU 2023-07 on January 1, 2024. There was no material effect on its condensed consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024, on a prospective basis, with a retrospective option, and early adoption is permitted. The Company plans to adopt ASU 2023-09 for the year ending December 31, 2025, and is currently evaluating the impact of adoption of this standard on its consolidated financial statements and disclosures.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) and in January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses.

The transition method is prospective with the retrospective method permitted and will be effective for the Company's annual period ending December 31, 2027 and interim periods for the interim period beginning January 1, 2028. The Company is currently evaluating the impact of adoption of this standard on its consolidated financial statements and disclosures.

As of June 30, 2025, we had 885 franchised clinics in operation, 92 clinic licenses sold but not yet developed and 60 executed letters of intent for future clinic licenses. The franchise arrangement is documented in the form of a franchise agreement. The franchise arrangement requires the Company to perform various activities to support the brand that do not directly transfer goods and services to the franchisee, but instead represent a single performance obligation, which is the transfer of the franchise license. The intellectual property subject to the franchise license is symbolic intellectual property as it does not have significant standalone functionality and substantially all of the utility is derived from its association with the Company’s past or ongoing activities. The nature of the Company’s promise in granting the franchise license is to provide the franchisee with access to the brand’s symbolic intellectual property over the term of the license. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation.

The transaction price in a standard franchise arrangement primarily consists of (a) initial franchise fees, (b) continuing franchise fees (royalties), (c) advertising fees, and (d) software fees. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which otherwise requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price).

The Company recognizes the primary components of the transaction price as follows:

•Initial and renewal franchise fees, as well as transfer fees, are recognized as revenue ratably on a straight-line basis over the term of the respective franchise agreement, commencing with the execution of the franchise, renewal or transfer agreement. As these fees are typically received in cash at or near the beginning of the contract term, the cash received is initially recorded as a contract liability until recognized as revenue over time.

•The Company is entitled to royalties and advertising fees based on a percentage of the franchisee’s gross sales as defined in the franchise agreement. Royalty and advertising revenue are recognized when the franchisee’s sales occur. Depending on timing within a fiscal period, the recognition of revenue results in either what is considered a contract asset (unbilled receivable) or, once billed, accounts receivable, on the condensed consolidated balance sheet.

•The Company is entitled to a software fee, which is charged monthly. The Company recognizes revenue related to software fees ratably on a straight-line basis over the term of the franchise agreement.

In determining the amount and timing of revenue from contracts with customers, the Company exercises significant judgment with respect to collectability of the amount; however, the timing of recognition does not require significant judgment as it is based on either the franchise term or the reported sales of the franchisee, neither of which requires estimation. The Company believes its franchising arrangements do not contain a significant financing component.

The Company recognizes advertising fees received under franchise agreements as advertising fund revenue.

Sales commissions earned by the regional developers and the Company’s sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.

The Company believes that the captions contained on the condensed consolidated income statements appropriately reflect the disaggregation of its revenue by major type for the three and six months ended June 30, 2025 and 2024. Other revenues primarily consist of merchant income associated with preferred vendor royalties associated with franchisees’ credit card transactions.

The following table shows the Company’s revenues disaggregated according to the timing of transfer of services:

Changes in the Company’s accounts receivable, net during the six months ended June 30, 2025 were as follows:

Changes in the Company’s contract liability for deferred franchise fees during the six months ended June 30, 2025 were as follows:

The Company’s deferred franchise and development costs represent capitalized sales commissions. Changes during the six months ended June 30, 2025 were as follows:

The following table illustrates estimated revenues expected to be recognized in the future related to performance obligations that were unsatisfied (or partially unsatisfied) as of June 30, 2025:

In 2023, the Company initiated plans to refranchise the majority of its company-owned or managed clinics with plans to retain a small portion of high-performing clinics. During the third quarter of 2024, the Company expanded the refranchising plan to include additional clinic markets of company-owned or managed clinics, marketing the clinics in clusters grouped by proximity to larger private equity firms. Because the Company has formalized a plan to sell its entire corporate clinic reportable segment, the Company has concluded that the overall refranchising plan represents a strategic shift that will have a major effect on the Company’s operations and financial results.

As of December 31, 2024, the corporate clinics classified as held for sale or already sold under the refranchising plan represent, in the aggregate, a strategic shift that will have a major effect on the Company’s operations and financial results. Accordingly, the results of the corporate clinic segment and its assets and liabilities are reported separately as discontinued operations in the condensed consolidated income statements and condensed consolidated balance sheets. As permitted, the Company elected not to adjust the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024 to exclude cash flows attributable to discontinued operations. Accordingly, the Company disclosed the depreciation and amortization, capital expenditures and significant operating and investing non-cash items related to the corporate clinic segment below.

The key components of Net income from discontinued operations that were included in the Company’s condensed consolidated income statements are as follows:

The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in the Company’s condensed consolidated balance sheets:

The key components of cash flows from discontinued operations are as follows:

The clustered clinics are in varying stages of sales negotiations with approximately all of the Company’s corporate clinic portfolio expected to be recognized as a completed sale within one year with an estimated fair value of $6.4 million at June 30, 2025. Effective with the designation as held for sale, the Company discontinued recording depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics as required by GAAP. The Company reported the related assets and liabilities of the clinics as held for sale as discontinued operations in its June 30, 2025 and December 31, 2024 condensed consolidated balance sheets.

Long-lived assets that meet the criteria for the held for sale designation are reported at the lower of their carrying value or fair value less estimated cost to sell. As a result of its evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the clinics estimated fair values, the Company recorded an estimated loss on disposal of $0.4 million and $0.5 million for the three months ended June 30, 2025 and 2024, respectively, and an estimated loss of $1.4 million and $0.7 million for the six months ended June 30, 2025 and 2024, respectively. A valuation allowance of $5.7 million and $5.1 million was included in discontinued operations current assets in its condensed consolidated balance sheets as of June 30, 2025 and December 31, 2024, respectively.

During the six months ended June 30, 2025, in connection with the sale of company-owned or managed clinics classified as held for sale as of December 31, 2024 for a combined sales price of $7.8 million, the Company sold $16.1 million assets held for sale, net of a valuation allowance of $1.0 million and $7.2 million of liabilities to be disposed of in the consolidated balance sheets as of December 31, 2024. As a result of the sales, the Company incurred $0.4 million in selling costs and recorded a loss of $0.6 million included in Income from discontinued operations before income tax expense on the condensed consolidated income statement for the six months ended June 30, 2025.

The principal components of the held for sale assets and liabilities to be disposed of as of June 30, 2025 and December 31, 2024 were as follows:

The pre-tax income of the clinics designated as held for sale was $1.3 million and $0.7 million for the three months ended June 30, 2025 and 2024, respectively, the results of which exclude the allocation of overhead. The pre-tax income of the clinics designated as held for sale was $2.2 million and $2.2 million for the six months ended June 30, 2025 and 2024, respectively, the results of which exclude the allocation of overhead.

Property and equipment consisted of the following:

Depreciation expense was $0.4 million and $0.3 million for the three months ended June 30, 2025 and 2024, respectively. Depreciation expense was $0.8 million and $0.7 million for the six months ended June 30, 2025 and 2024, respectively.

Construction in progress at June 30, 2025 and December 31, 2024, related primarily to internal use software in development.

The Company’s financial instruments include cash, restricted cash, accounts receivable, accounts payable, accrued expenses and debt under the Credit Agreement (as defined in Note 6, Debt). The carrying amounts of its financial instruments, excluding the debt under the Credit Agreement, approximate their fair value due to their short maturities. The carrying value of the Company’s debt under the Credit Agreement approximates fair value due to its interest rate being calculated from observable quoted prices for similar instruments, which is considered a Level 2 fair value measurement.

Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:

Level 1:    Observable inputs such as quoted prices in active markets;

Level 2:    Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3:    Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

As of June 30, 2025 and December 31, 2024, the Company did not have any financial instruments that were measured on a recurring basis as Level 1, 2 or 3.

The Company’s non-financial assets, included in both continuing and discontinued operations, which primarily consist of goodwill, intangible assets, property, plant and equipment, and operating lease ROU assets, are not required to be measured at fair value on a recurring basis, and instead are reported at their carrying amount. However, on a periodic basis whenever events or changes in circumstances indicate that their carrying amount may not be fully recoverable (and at least annually for goodwill), non-financial assets are assessed for impairment. If the fair value is determined to be lower than the carrying amount, an impairment charge is recorded to write down the asset to its fair value, which is considered Level 3 within the fair value hierarchy.

Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. The estimated fair values of the company-owned or managed clinics classified as Held for Sale (see Note 3, Divestitures) were recorded in discontinued operations current assets at fair values on a nonrecurring basis and are based upon Level 2 inputs, which include a potential buyer agreed-upon selling price or Level 3 inputs, which includes a market approach using a multiple of earnings assumption based on clinic-level historical financial performance as well as an income approach using discounted cash flow ("DCF") models that use significant unobservable inputs and assumptions. Key inputs in the DCF models included projected cash flows over a 10-year forecast period, based on clinic-level historical financial performance and management's expectations of future operating results. A terminal value was estimated using a terminal year cash flow multiple for locations with positive cash flows. For locations with projected negative cash flows, no terminal value was assigned, as these clinics were assumed to cease operations upon lease termination. The future cash flows and terminal value were discounted to present value using a discount rate of 14.5% that reflects the risk profile of the underlying operations and market conditions as of the measurement date. The Company, where appropriate, equally weights the market approach and income approach in its valuation.

Assets held for sale as of June 30, 2025 and December 31, 2024 include all company-owned or managed clinics. The fair value measurement of the assets held for sale as of June 30, 2025 was recorded as $0.1 million based upon Level 2 inputs and $6.3 million based upon Level 3 inputs. The Company maintains a valuation allowance of $5.7 million to adjust the carrying value of the disposal group to fair value less cost to sell as of June 30, 2025. The fair value of the assets held for sale as of December 31, 2024 was valued as $0.4 million based upon Level 2 inputs and $26.9 million based upon Level 3 inputs and carried a valuation allowance of $5.1 million to adjust the carrying value of the disposal group to fair value less cost to sell as of December 31, 2024.

Long-lived assets classified as held and used where the asset group was not determined to be recoverable are tested for impairment. No impairment was recorded for asset groups classified as held and used during the three and six months ended June 30, 2025. In connection with the planned sale or determined closure of certain company-owned or managed clinics long-lived assets classified as held and used where the asset group was not determined recoverable, the Company recorded an impairment loss of $0.8 million and $0.9 million included in Income from discontinued operations before income tax expense in its condensed consolidated income statements for the three and six months ended June 30, 2024, respectively. The asset group was determined to be at the clinic level, as this is the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The long-lived assets fair values were determined by the following: Level 2 inputs where available, which included using a valuation multiple (e.g, price per square foot) based on observable prices for comparable long-lived assets; and Level 3 inputs, which included the multiple of earnings approach using the Company's historical earnings trend data, comparable historical asset sales by the Company and franchisees that were not exact matches, and (for calculating the fair value of intangible assets specifically) the Company’s historical experience, future projections and comparable market data include future cash flows, long-term growth rates, attrition rates and discount rates. The carrying value of these asset groups impaired to their fair value included ROU assets of $476,983, were written down to $95,870 determined by Level 1 and Level 2 inputs. The carrying values of these asset groups impaired to their fair value included fixed assets of $1.9 million that were written down to $1.4 million and reacquired rights of $298,510 that were written down to $252,746 both determined by Level 3 inputs discussed above. Generally, a change in the assumption used for the multiple inputs would have resulted in a directionally similar change of the fair value measurement where a multiple of earnings assumption was used.

On February 28, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., individually and as Administrative Agent and Issuing Bank (the “Lender”). The Credit Agreement provided for senior secured credit facilities (the “Credit Facilities”) in the amount of $7,500,000, including a $2,000,000 revolver (the "Revolver") and a $5,500,000 development line of credit (the "Line of Credit"). The Revolver included amounts available for letters of credit of up to $1,000,000 and an uncommitted additional amount of $2,500,000. All outstanding principal and interest on the Revolver was due on February 28, 2022.

On February 28, 2022, the Company entered into an amendment to its Credit Facilities (as amended, the “2022 Credit Facility”) with the Lender. Under the 2022 Credit Facility, the Revolver increased to $20,000,000 (from $2,000,000), the portion of the Revolver available for letters of credit increased to $5,000,000 (from $1,000,000), the uncommitted additional amount increased to $30,000,000 (from $2,500,000) and the developmental Line of Credit of $5,500,000 was terminated. The Revolver will be used for working capital needs, general corporate purposes and for acquisitions, development and capital improvement uses. At the option of the Company, borrowings under the 2022 Credit Facility bear interest at: (i) the adjusted Secured Overnight Financing Rate (“SOFR"), plus 0.10%, plus 1.75%, payable on the last day of the selected interest period of one, three or six months and on the three-month anniversary of the beginning of any six-month interest period, if applicable; or (ii) an Alternative Base Rate ("ABR"), plus 1.00%, payable monthly. The ABR is the greatest of (A) the prime rate (as published by the Wall Street Journal); (B) the Federal Reserve Bank of New York rate, plus 0.5%; and (C) the adjusted one-month term SOFR. Amounts outstanding under the Revolver on February 28, 2022 continued to bear interest at the rate selected under the Credit Facilities prior to the amendment until the last day of the interest period in effect, at which time, if not repaid, the amounts outstanding under the Revolver will bear interest at the 2022 Credit Facility rate. As a result of this refinance, $2,000,000 of current maturity of long-term debt was reclassified to long-term as of December 31, 2021. The 2022 Credit Facility will terminate, and all principal and interest will become due and payable on the fifth anniversary of the amendment, which will occur on February 28, 2027. On January 17, 2024, the Company paid down the outstanding balance on its Debt under the Credit Agreement of $2,000,000.

The Credit Facilities contain customary events of default, including but not limited to nonpayment; material inaccuracy of representations and warranties, violations of covenants, certain bankruptcies and liquidations, cross-default to material indebtedness, certain material judgments, and certain fundamental changes such as a merger or sale of substantially all assets (as further defined in the Credit Facilities). The Credit Facilities require the Company to comply with customary affirmative, negative and financial covenants, including minimum interest coverage and maximum net leverage. A breach of any of these operating or financial covenants would result in a default under the Credit Facilities. If an event of default occurs and is continuing, the lenders could elect to declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. The Credit Facilities are collateralized by substantially all of the Company’s assets, including the assets in the Company’s company-owned or managed clinics. As of June 30, 2025, the Company was in compliance with all applicable financial and non-financial covenants under the Credit Agreement, and there is no outstanding balance as of June 30, 2025.

The Company grants stock-based awards under its 2024 Incentive Stock Plan (the “2024 Plan”). The shares issued as a result of stock-based compensation transactions generally have been funded with the issuance of new shares of the Company’s common stock. The Company may grant the following types of incentive awards under the 2024 Plan: (i) non-qualified stock options; (ii) incentive stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) restricted stock units. Each award granted under the 2024 Plan is subject to an award agreement that incorporates, as applicable, the exercise price, the term of the award, the periods of restriction, the number of shares to which the award pertains and such other terms and conditions as the plan committee determines. Awards granted under the 2024 Plan are classified as equity awards, which are recorded in stockholders’ equity in the Company’s condensed consolidated balance sheets. Through June 30, 2025, the Company has granted under the 2024 Plan (i) non-qualified stock options; (ii) incentive stock options; and (iii) restricted stock. There were no stock appreciation rights and restricted stock units granted under the 2024 Plan as of June 30, 2025.

The Company’s closing price on the date of grant is the basis of fair value of its common stock used in determining the value of share-based awards. To the extent the value of the Company’s share-based awards involves a measure of volatility, the Company uses available historical volatility of the Company’s common stock over a period of time corresponding to the expected stock option term. The Company uses the simplified method to calculate the expected term of stock option grants to employees as the Company does not have sufficient comparable historical exercise data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. Accordingly, the expected life of the options granted is based on the average of the vesting term, which is generally four years and the contractual term, which is generally ten years. The Company will continue to evaluate the appropriateness of utilizing such method. The risk-free interest rate is based on United States Treasury yields in effect at the date of grant for periods corresponding to the expected stock option term. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.

The Company did not grant options during the three and six months ended June 30, 2025 and 2024.

The information below summarizes the stock option activity for six months ended June 30, 2025:

For the three months ended June 30, 2025 and 2024, stock-based compensation expense for stock options was $17,040 and $47,037, respectively. For the six months ended June 30, 2025 and 2024, stock-based compensation expense for stock options was $38,681 and $101,775, respectively.

Restricted stock awards granted to employees generally vest in four equal annual installments, although on March 5, 2024, the Company granted 29,454 shares of restricted stock as part of a special award to certain executive employees that vested in one installment on the first anniversary of the grant. Restricted stock awards granted to non-employee directors typically vest in full one year after the date of grant.

The information below summarizes the restricted stock activity for the six months ended June 30, 2025: